The degree is the first of its kind in the country, fulfilling a need to provide graduates with skills in the chemistry and biology of cancer, and direct experience of some of the very latest research in the field.
The course will cover new approaches to cancer diagnosis and treatment and involve the design and synthesis of small molecule cancer drugs, equipping graduates for employment in the pharmaceutical industry and in academia.
The pioneering degree has been developed by Dr. Paul Jenkins from the Department of Chemistry, who has research expertise in the development of chemotherapeutic drugs.
He said “I think that this unique course will equip graduates to take part in the exciting and rewarding field of anti-cancer drug development. It will explain the biological pathways involved in cancer and how to design non-toxic small molecules to intervene specifically in these pathways to produce the next generation of cancer drugs.”
The main issue with cancer chemotherapy at the moment is that it is based on selective toxicity of the cancer drug for the tumour cells. This selectivity is never perfect and the treatments have considerable side effects.
One of the newest cancer drugs is Gleevec which is a specific non toxic inhibitor of a key protein in a cancer control pathway. Future developments will involve drugs of this type.
Leicester is a national centre for clinical research in the field of cancer. The Chemistry Department is conducting research funded by CRUK to develop non-toxic inhibitors of a key check-point enzyme in the cell division process.
In cancer cells, growth is very rapid and one way to combat this is to stop cells dividing by specific inhibition of the enzymes that control the cell cycle. “Our results have been encouraging” said Dr. Jenkins, “and two of our researchers will present results at a medicinal chemistry conference in Lille later this year.”
The degree is aimed at graduates in chemistry or a related discipline and non-graduates with appropriate experience. Cancer Research UK has supplied three bursaries covering fees and stipend for UK and EEA students taking the MSc in Cancer Chemistry.
Ather Mirza | alfa
Closing the carbon loop
08.12.2016 | University of Pittsburgh
Newly discovered bacteria-binding protein in the intestine
08.12.2016 | University of Gothenburg
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Life Sciences
08.12.2016 | Physics and Astronomy
08.12.2016 | Materials Sciences